It is important to be clear from the outset: medical cannabis is not a first-line treatment for menopause in the UK, and it is not prescribed for menopause as a primary indication. Hormone replacement therapy (HRT) is the most effective and evidence-based treatment for menopausal symptoms, and NICE's Menopause guideline (NG23, updated 2023) recommends offering HRT to women with menopausal symptoms where there is no clinical contraindication. This page is for women who are either already on HRT or unable to take it, and who experience comorbid symptoms — chronic pain, sleep disturbance, or anxiety — that remain inadequately managed. Those specific symptoms, when clinically significant, may be eligible for cannabis-based prescribing in their own right.

What Menopause Is and How Symptoms Develop

Menopause is defined as 12 consecutive months without menstruation, occurring at a median age of 51 in the UK, though the perimenopause — the transition period — can begin years earlier. The decline in oestrogen and progesterone during this transition affects multiple body systems. Vasomotor symptoms (hot flushes and night sweats) are the most commonly reported, but a significant proportion of women experience sleep disturbance, musculoskeletal pain, joint aches, mood changes, anxiety, cognitive effects, and genitourinary symptoms.

For some women, these symptoms are mild and transient. For others, they significantly impair quality of life for years. Women who have contraindications to HRT — including certain breast cancer histories, active thromboembolic disease, or personal preference — may have fewer pharmacological options. It is within this population, and specifically for the comorbid symptom clusters of pain, sleep disruption, and anxiety, that cannabis-based medicines are increasingly discussed.

Why Cannabis Is Not Prescribed for Menopause Itself

Menopause is a physiological transition, not a disease in the traditional sense. The primary driver of menopausal symptoms is hormonal change, and HRT addresses this directly. Cannabis-based medicines do not modulate oestrogen or progesterone levels, and there is no clinical basis for prescribing them to address hormonal decline per se. NICE NG23 (2023) does not mention cannabinoids as a treatment option for menopausal symptoms.

UK private cannabis clinics will not prescribe cannabis for a patient whose stated condition is simply "menopause" without a documented comorbid symptom that meets eligibility criteria in its own right. A patient presenting with chronic musculoskeletal pain that predates or is significantly worsened by menopause, for example, may be eligible under a chronic pain indication. A patient with clinical anxiety that is exacerbated during the perimenopause may be eligible under an anxiety indication. The menopause itself is not the prescribing indication — the specific comorbid symptom is.

Chronic Pain and Menopause

Oestrogen has anti-inflammatory and analgesic properties, and the decline in oestrogen during menopause is associated with increased sensitivity to pain in some women. Fibromyalgia, which is more prevalent in women, often worsens during the perimenopause and postmenopause. Musculoskeletal pain, joint aches, and inflammatory conditions can all be exacerbated by hormonal transition. Women with pre-existing chronic pain conditions may find their symptoms significantly worsen during this period.

For these patients, cannabis-based medicines may be appropriate under a chronic pain indication if the clinical criteria are met: documented pain condition, history of trials of conventional treatments (including physiotherapy, non-steroidal anti-inflammatory drugs, and relevant prescription medications), and specialist assessment confirming the appropriateness of cannabis-based medicine. The fact that menopause contributes to or exacerbates the pain is relevant clinical context, but it does not change the prescribing pathway.

Sleep Disturbance and Menopause

Sleep disruption is among the most commonly reported and most impactful menopausal symptoms. Night sweats, anxiety, and direct hormonal effects on sleep architecture all contribute. For women who have tried HRT (or cannot take it) and continue to experience significant insomnia linked to a clinical condition, cannabis-based medicines — particularly CBD-dominant or balanced THC:CBD formulations — may be considered for the sleep-related indication where it is comorbid with another qualifying condition such as anxiety or chronic pain.

It should be noted that insomnia alone, without a comorbid qualifying condition, is unlikely to be sufficient grounds for cannabis prescribing in the UK. The clinical pathway for sleep disorders in the UK context requires documented comorbidity. Women experiencing menopausal sleep disruption should first ensure adequate trials of sleep hygiene, HRT (where eligible), and cognitive behavioural therapy for insomnia (CBTi) before seeking a cannabis-based medicine assessment.

Anxiety and Menopause

Anxiety disorders — including generalised anxiety disorder and panic disorder — occur at elevated rates during the perimenopause and postmenopause. Hormonal fluctuation directly affects neurotransmitter systems including serotonin and GABA pathways. Women with no prior history of anxiety may develop it during this transition; those with pre-existing anxiety may experience significant worsening. Where anxiety meets clinical criteria and conventional treatment has been inadequate, a specialist may consider cannabis-based medicines as an adjunctive option under an anxiety indication.

Accessing an Assessment

Women seeking medical cannabis for menopause-related comorbidities should approach a private cannabis clinic prepared to articulate the specific symptom they are seeking help for — whether that is chronic pain, sleep disruption, or anxiety — and to provide documentation of their relevant treatment history. Presenting menopause itself as the indication is unlikely to result in a prescription. Presenting a well-documented comorbid symptom that has not adequately responded to conventional treatments is the appropriate clinical pathway.

A GP referral is not required by most private cannabis clinics, but GP records confirming the relevant diagnosis and treatment history are typically required. See the UK medical cannabis clinics directory and how to get a medical cannabis prescription in the UK for further guidance.

Frequently Asked Questions — Medical Cannabis and Menopause UK

Can I get a medical cannabis prescription specifically for menopause in the UK?

Not for menopause as a primary indication. UK specialists prescribe cannabis-based medicines for specific symptoms — such as chronic pain, anxiety, or sleep disorders linked to a clinical condition — not for menopause as such. If you have a comorbid symptom that meets eligibility criteria in its own right, that symptom is the prescribing indication, not the menopause itself.

Should I try HRT before seeking medical cannabis?

Yes, if HRT is appropriate for you. NICE NG23 (2023) recommends HRT as the most effective treatment for menopausal symptoms. Medical cannabis is not a substitute for HRT. If you are unable to take HRT or if specific comorbid symptoms remain inadequately managed on HRT, that is the context in which cannabis-based medicines might be relevant.

Can medical cannabis help with hot flushes?

There is no established clinical evidence that cannabis-based medicines reduce vasomotor symptoms such as hot flushes and night sweats. These symptoms are driven by hormonal changes that cannabinoids do not address. HRT remains the appropriate treatment. Cannabis is not indicated for vasomotor menopausal symptoms.

I have chronic joint pain that got much worse since the perimenopause. Can I qualify?

If you have a documented chronic pain condition that has not responded adequately to conventional treatments, you may be eligible for a cannabis prescription under a chronic pain indication. The fact that perimenopause has worsened your pain is clinically relevant context. The prescribing indication would be the chronic pain condition, not the menopause, but the clinical picture is assessed as a whole.

Will cannabis-based medicines interact with HRT?

Cannabinoids are metabolised via the CYP450 enzyme system, and in principle there may be interactions with some forms of HRT. Current evidence on clinically significant interactions between cannabis-based medicines and hormonal therapy is limited. Full disclosure of all current medications — including HRT formulation and route of administration — is essential at your specialist consultation.

How Much Does Medical Cannabis Cost for Menopause in the UK?

• Initial consultation: £79 to £200 depending on the clinic.
• Monthly medication: £100 to £400 per month, depending on product type and dose.
• Follow-up appointments: £50 to £100 per session, typically every one to three months.

Compare the full cost structure — including whether follow-up appointments are included in a monthly package — before committing to a clinic. See the full UK cost guide for a detailed breakdown.